Diabetes drug to treat chronic kidney disease in adults has licence extension granted

The Medicines and Healthcare products Regulatory Agency has granted a licence extension for dapagliflozin, after promising trial results.
Diabetes drug Farxiga (dapagliflozin)
David Wheeler, professor of kidney medicine at University College London, said the MHRA's decision "provides healthcare professionals with an effective new option that can slow progression of disease and possibly delay the need for dialysis"

REUTERS / Alamy Stock Photo

A decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to grant a licence extension for dapagliflozin (Forxiga; AstraZeneca) for the treatment of chronic kidney disease (CKD) in adult patients has been hailed as a “significant milestone” in the treatment of the disease.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated